Scinai Immunotherapeutics Ltd. (SCNI) stock
SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.37−0.01 (-1.40%)
Close on Nov 18, 2026Market cap $1.27MP/E –Yield –
Scinai Immunotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$7.54M. The highest annual figure on record is -$7.54M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.54M | – |
| FY2024 | Dec 31, 2024 | -$8.64M | – |
| FY2023 | Dec 31, 2023 | -$9.71M | – |
| FY2022 | Dec 31, 2022 | -$11.06M | – |
| FY2021 | Dec 31, 2021 | -$10.86M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$2.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.62M | – |
See a number that looks wrong?